EMA Committee Backs Two Biosimilar Insulin Aspart Medicines and Warns Mounjaro May Make the Pill Less Reliable
At its November 9-12 meeting, the CHMP adopted positive opinions for Garzulys and Donrafylix, two biosimilar versions of the mealtime insulin aspart for adults and children aged 1 and older. The committee also adopted a letter to health professionals on Mounjaro (tirzepatide) and oral contraceptives: women using the pill are advised to add a barrier method for 4 weeks after starting Mounjaro and after each dose increase, or switch to a non-oral method.